SFY Relative Valuation - Theriva Biologics Inc - Alpha Spread

Theriva Biologics Inc
F:SFY

Watchlist Manager
Theriva Biologics Inc Logo
Theriva Biologics Inc
F:SFY
Watchlist
Price: 2.42 EUR Market Closed
Market Cap: 41.8m EUR
Have any thoughts about
Theriva Biologics Inc?
Write Note

Relative Value

There is not enough data to reliably calculate the relative value of SFY.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SFY Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.7
vs History
vs Industry
Median 3Y
-14.4
Median 5Y
-13.8
Industry
23.9
Forward
-2.5
vs History
vs Industry
Median 3Y
-15.3
Median 5Y
-15.2
Industry
22.2
vs History
vs Industry
Median 3Y
-14.4
Median 5Y
-14.9
Industry
24
vs History
vs Industry
Median 3Y
5.7
Median 5Y
10.5
Industry
2.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-10.6
Industry
5.1
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-9.9
Industry
4.7
Forward
-1
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-12.1
Industry
6.6
vs History
vs Industry
Median 3Y
-11.3
Median 5Y
-11.3
Industry
4.7
vs History
vs Industry
Median 3Y
6.7
Median 5Y
7.2
Industry
4.7

Multiples Across Competitors

SFY Competitors Multiples
Theriva Biologics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Theriva Biologics Inc
F:SFY
41.5m EUR 0 -2.4 -1.3 -1.3
US
Abbvie Inc
NYSE:ABBV
340.7B USD 6.2 64.3 15.7 24.1
US
Amgen Inc
NASDAQ:AMGN
179.6B USD 5.8 57.4 20.1 36.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
127B USD 9.4 29.4 25.8 28.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.5B USD 11.9 -252.1 26.8 28.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 975 -504 -548.8 -534.2
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
AU
CSL Ltd
ASX:CSL
142.8B AUD 6.5 36.5 22.3 27.8
US
Seagen Inc
F:SGT
39.3B EUR 19 -58.3 -62.8 -56.7
US
Palatin Technologies Inc
LSE:0KF3
40.1B USD 6 792.6 -1 219.7 -1 236.1 -1 223.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.9B USD 14.9 -479.1 210.8 324.5
P/E Multiple
Earnings Growth
US
Theriva Biologics Inc
F:SFY
Average P/E: 57.4
Negative Multiple: -2.4
N/A
US
Abbvie Inc
NYSE:ABBV
64.3
406%
US
Amgen Inc
NASDAQ:AMGN
57.4
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.4
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.1
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
AU
CSL Ltd
ASX:CSL
36.5
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 219.7 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -479.1 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Theriva Biologics Inc
F:SFY
Average EV/EBITDA: 47.3
Negative Multiple: -1.3
N/A
US
Abbvie Inc
NYSE:ABBV
15.7
28%
US
Amgen Inc
NASDAQ:AMGN
20.1
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.8
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.8 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
AU
CSL Ltd
ASX:CSL
22.3
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -62.8 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 236.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
210.8
N/A
EV/EBIT Multiple
EBIT Growth
US
Theriva Biologics Inc
F:SFY
Average EV/EBIT: 68.8
Negative Multiple: -1.3
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.5
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.6
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.2 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
AU
CSL Ltd
ASX:CSL
27.8
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 223.4 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
324.5
N/A

See Also

Discover More
Back to Top